Form 4: United Therapeutics CEO Rothblatt Transfers Shares Between Family Trusts

Martine Rothblatt, CEO of United Therapeutics, reports a transfer of shares between family trusts in a recent SEC filing.

Summary

• Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp, filed a Form 4 with the SEC on March 11, 2025.
• The filing details a transaction on March 7, 2025, involving a gift of United Therapeutics common stock from a family trust where Rothblatt is the settlor with power to revoke, to a family trust where Rothblatt's spouse is the settlor with power to revoke.
• The transaction involved 229,947 shares.
• Following the transaction, Rothblatt directly owns 130 shares of common stock.
• Rothblatt indirectly owns 15,962 shares through a trust where she is the sole trustee and beneficiary or co-trustee and settlor with power to revoke.
• Rothblatt indirectly owns 258,117 shares through a trust where her spouse is the sole trustee and beneficiary or co-trustee and settlor with power to revoke.
• Rothblatt indirectly owns 324,518 shares through a trust where she shares investment power and she and/or immediate family members are beneficiaries.
• Rothblatt indirectly owns 45,596 shares through a trust where her spouse shares investment power and she and/or immediate family members are beneficiaries.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a share transfer. It doesn't convey any positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's financial health or strategic direction.

Key Dates